Christelle Gateau

Dr. Christelle Gateau


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2002 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
LKLydia Karmazin
Lydia Karmazin
MMMarinella Mazzanti
Marinella Mazzanti
CGChristelle Gateau
Christelle Gateau
CHClément Hill
Clément Hill
JPJacques Pécaut
Jacques Pécaut
The existence of a strong correlation between ligand architecture and metal ion binding selectivity is demonstrated through large differences in the separation efficiencies found in the selective extraction of Am3+ from an acidic mixture of Am3+ and Eu3+ for three new tetrapodal hexadentate ligands containing four 2-pyrazinylmethyl groups attached to three different diamino spacers.

2 October 2020 in Journal of Drug Targeting
Verified
Journal Article
Open access
LGLaura Gauthier
Laura Gauthier
MCMireille Chevallet
Mireille Chevallet
FBFrancois Bulteau
Francois Bulteau
MTMichel Thépaut
Michel Thépaut
PDPascale Delangle
Pascale Delangle
CGChristelle Gateau
Christelle Gateau
Liver is the main organ for metabolism but is also subject to various pathologies, from viral, genetic, cancer or metabolic origin. There is thus a crucial need to develop efficient liver-targeted drug delivery strategies. Asialoglycoprotein receptor (ASGPR) is a C-type lectin expressed in the hepatocyte plasma membrane that efficiently endocytoses glycoproteins exposing galactose (Gal) or N-acetylgalactosamine (GalNAc). Its targeting has been successfully used to drive the uptake of small molecules decorated with three or four GalNAc, thanks to an optimization of their spatial arrangement. Herein, we assessed the biological properties of highly stable nanostructured lipid carriers (NLC) made of FDA-approved ingredients and formulated with increasing amounts of GalNAc. Cellular studies showed that high density of GalNAc was required to favour hepatocyte internalization via the ASGPR pathway. Interaction studies using surface plasmon resonance and the Macrophage Galactose-Lectin as GalNAc-recognizing lectin confirmed the need of high GalNAc density for specific recognition of these NLC. This work is a first step for the development of efficient nanocarriers for prolonged liver delivery of active compounds.

11 November 2019 in Nanoscale Horizons
Verified
Journal Article
Open access
PDF file
MMMarianne Marchioni
Marianne Marchioni
GVGiulia Veronesi
Giulia Veronesi
IWIsabelle Worms
Isabelle Worms
WLWai Li Ling
Wai Li Ling
TGThomas Gallon
Thomas Gallon
ADAurélien Deniaud
Aurélien Deniaud
Silver nanoparticles (AgNPs) are efficient biocides increasingly used in consumer products and medical devices. Their activity is due to their capacity to release bioavailable Ag(I) ions making them long-lasting biocides but AgNPs themselves are usually easily released from the product. Besides, AgNPs are highly sensitive to various chemical environments that triggers their transformation, decreasing their activity. Altogether, widespread use of AgNPs leads to bacterial resistance and safety concerns for humans and the environment. There is thus a crucial need for improvement. Herein, a proof of concept for a novel biocide based on AgNP assemblies bridged together by a tri-thiol bioinspired ligand is presented. The final nanomaterial is stable and less sensitive to chemical environments with AgNPs completely covered by organic molecules tightly bound via their thiol functions. Therefore, these AgNP assemblies can be considered as safer-by-design and innovative biocides, since they deliver a sufficient amount of Ag(I) for biocidal activity with no release of AgNPs, which are insensitive to transformations in the nanomaterial.

13 May 2020 in Metallomics
Verified
Journal Article
Closed access
PDF file
MMMarie Monestier
Marie Monestier
APAnaïs M Pujol
Anaïs M Pujol
ALAline Lamboux
Aline Lamboux
MCMartine Cuillel
Martine Cuillel
IPIsabelle Pignot-Paintrand
Isabelle Pignot-Paintrand
EMElisabeth Mintz
Elisabeth Mintz
Copper chelation is the most commonly used therapeutic strategy nowadays to treat Wilson’s disease, a genetic disorder primarily inducing a pathological accumulation of Cu in the liver. The mechanism of action of Chel2, a liver-targeting Cu(i) chelator known to promote intracellular Cu chelation, was studied in hepatic cells that reconstitute polarized epithelia with functional bile canaliculi, reminiscent of the excretion pathway in the liver. The interplay between Chel2 and Cu localization in these cells was demonstrated through confocal microscopy using a fluorescent derivative and nano X-ray fluorescence. The Cu(i) bound chelator was found in vesicles potentially excreted in the canaliculi. Moreover, injection of Chel2 either intravenously or subcutaneously to a murine model of Wilson’s disease increased excretion of Cu in the faeces, confirming in vivo biliary excretion. Therefore, Chel2 turns out to be a possible means to collect and excrete hepatic Cu in the faeces, hence restoring the physiological pathway.

9 May 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
FLFanny Laporte
Fanny Laporte
YCYves Chenavier
Yves Chenavier
ABAlexandra Botz
Alexandra Botz
CGChristelle Gateau
Christelle Gateau
CLColette Lebrun
Colette Lebrun
PDPascale Delangle
Pascale Delangle
Determining the affinity of proteins for uranyl is key to understand the toxicity of this cation and to further develop decorporation strategies. However, usual techniques to achieve that goal often require specific equipment and expertise. Here, we propose a simple, efficient, fluorescence‐based method to assess the affinity of proteins and peptides for uranyl, at equilibrium and in buffered solution. We first designed and characterized an original uranyl‐binding fluorescent probe. We then built a reference scale for uranyl affinity in solution, relying on signal quenching of our fluorescent probe in presence of high‐affinity uranyl‐binding peptides. We finally validated our approach by re‐evaluating the uranyl‐binding affinity of four native proteins. We envision that this tool will facilitate the reliable and reproducible assessment of affinities of peptides and proteins for uranyl.

Verified
Journal Article
Open access
PDF file
LGLaura Gauthier
Laura Gauthier
MVMathieu Varache
Mathieu Varache
ACAnne-Claude Couffin
Anne-Claude Couffin
CLColette Lebrun
Colette Lebrun
PDPascale Delangle
Pascale Delangle
ITIsabelle Texier
Isabelle Texier
Nanoparticles have been extensively studied for drug delivery and targeting to specific organs. The functionalization of the nanoparticle surface by site-specific ligands (antibodies, peptides, saccharides) can ensure efficient recognition and binding with relevant biological targets. One of the main challenges in the development of these decorated nanocarriers is the accurate quantification of the amount of ligands on the nanoparticle surface. In this study, nanostructured lipid carriers (NLC) were functionalized with N-acetyl-D-galactosamine (GalNAc) units, known to target the asialoglycoprotein receptor (ASGPR). Different molar percentages of GalNAc-functionalized surfactant (0%, 2%, 5%, and 14%) were used in the formulation. Based on ultra-high-performance liquid chromatography separation and evaporative light-scattering detection (UPLC-ELSD), an analytical method was developed to specifically quantify the amount of GalNAc units present at the NLC surface. This method allowed the accurate quantification of GalNAc surfactant and therefore gave some insights into the structural parameters of these multivalent ligand systems. Our data show that the GalNAc decorated NLC possess large numbers of ligands at their surface and suitable distances between them for efficient multivalent interaction with the ASGPR, and therefore promising liver-targeting efficiency.